Intellia, Gene Editing
Digest more
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Intellia’s in vivo CRISPR gene therapy for hereditary angioedema cut attack rates by 87% in a Phase III trial, prompting a rolling FDA submission. Novartis secured EU approval for the first oral ...
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation ...
Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
Rice University scientists used advanced CRISPR techniques to study PEX11, a protein coded by five genes in Arabidopsis plants, revealing its role in controlling peroxisome growth during the seed-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results